No data to show
XNAS
MYNZ
Market cap7mUSD
May 06, Last price
2.44USD
1D
-13.17%
1Q
-66.58%
IPO
-75.58%
Name
Mainz Biomed NV
Chart & Performance
P/E
—
P/S
8.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-39.26%
Rev. gr., 5y
26.01%
Revenues
894k
-0.17%
Net income
-22m
L-17.66%
CFO
-17m
L-22.10%
Profile
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 894 -0.17% | 895 69.00% | 530 -8.22% | |||
Cost of revenue | 18,933 | 27,198 | 26,819 | |||
Unusual Expense (Income) | ||||||
NOPBT | (18,039) | (26,302) | (26,289) | |||
NOPBT Margin | ||||||
Operating Taxes | 65 | |||||
Tax Rate | ||||||
NOPAT | (18,039) | (26,302) | (26,354) | |||
Net income | (21,651) -17.66% | (26,296) -0.59% | (26,453) 119.12% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 13,765 | 6,393 | 23,866 | |||
BB yield | -329.08% | -33.93% | -23.74% | |||
| Debt | ||||||
Debt current | 2,405 | 5,225 | 1,326 | |||
Long-term debt | 2,012 | 3,650 | 3,147 | |||
Deferred revenue | ||||||
Other long-term liabilities | 376 | 727 | ||||
Net debt | (1,818) | 1,804 | (12,669) | |||
| Cash flow | ||||||
Cash from operating activities | (17,090) | (21,939) | (14,770) | |||
CAPEX | (105) | (1,199) | (658) | |||
Cash from investing activities | (199) | (1,899) | (658) | |||
Cash from financing activities | 16,600 | 14,227 | 23,943 | |||
FCF | (17,381) | 771,980 | (827,239) | |||
| Balance | ||||||
Cash | 6,236 | 7,071 | 17,142 | |||
Long term investments | ||||||
Excess cash | 6,191 | 7,026 | 17,115 | |||
Stockholders' equity | (63,018) | (48,258) | (24,735) | |||
Invested Capital | 72,713 | 59,655 | 42,060 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 968 | 16,242 | 14,157 | |||
Price | 4.32 272.41% | 1.16 -83.66% | 7.10 -31.67% | |||
Market cap | 4,183 -77.80% | 18,841 -81.26% | 100,518 34.17% | |||
EV | 2,365 | 20,645 | 87,849 | |||
EBITDA | (17,022) | (25,436) | (25,909) | |||
EV/EBITDA | ||||||
Interest | 1,075 | 810 | 289 | |||
Interest/NOPBT | ||||||